Cell Death and Disease (Apr 2023)

Inhibition of the mitochondria-shaping protein Opa1 restores sensitivity to Gefitinib in a lung adenocarcinomaresistant cell line

  • Masafumi Noguchi,
  • Susumu Kohno,
  • Anna Pellattiero,
  • Yukino Machida,
  • Keitaro Shibata,
  • Norihito Shintani,
  • Takashi Kohno,
  • Noriko Gotoh,
  • Chiaki Takahashi,
  • Atsushi Hirao,
  • Luca Scorrano,
  • Atsuko Kasahara

DOI
https://doi.org/10.1038/s41419-023-05768-2
Journal volume & issue
Vol. 14, no. 4
pp. 1 – 10

Abstract

Read online

Abstract Drug resistance limits the efficacy of chemotherapy and targeted cancer treatments, calling for the identification of druggable targets to overcome it. Here we show that the mitochondria-shaping protein Opa1 participates in resistance against the tyrosine kinase inhibitor gefitinib in a lung adenocarcinoma cell line. Respiratory profiling revealed that oxidative metabolism was increased in this gefitinib-resistant lung cancer cell line. Accordingly, resistant cells depended on mitochondrial ATP generation, and their mitochondria were elongated with narrower cristae. In the resistant cells, levels of Opa1 were increased and its genetic or pharmacological inhibition reverted the mitochondrial morphology changes and sensitized them to gefitinib-induced cytochrome c release and apoptosis. In vivo, the size of gefitinib-resistant lung orthotopic tumors was reduced when gefitinib was combined with the specific Opa1 inhibitor MYLS22. The combo gefitinib-MYLS22 treatment increased tumor apoptosis and reduced its proliferation. Thus, the mitochondrial protein Opa1 participates in gefitinib resistance and can be targeted to overcome it.